enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

Core Viewpoint - enGene Holdings Inc. has amended its loan agreement with Hercules Capital to secure up to US$125 million in non-dilutive capital, enhancing its financial position [1]. Group 1 - enGene Holdings Inc. is a clinical-stage, non-viral genetic medicines company [1]. - The amendment to the loan and security agreement involves two of enGene's subsidiaries and Hercules Capital, Inc. as the agent [1]. - The additional capital is aimed at strengthening enGene's balance sheet [1].